Osiris inks deal with Stryker to commercialize bone matrix
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 12:19PM CST
OSIR: 14.87 (+0.13), SYK: 96.00 (-0.61)
Cell Therapy 2015: With Maturity Comes Promise
Life Sciences Report - Seeking Alpha - Wed Dec 24, 6:41AM CST
A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy - a disruptive technology that has, in the past few years, progressed out of preclinical...
KOOL: 1.13 (+0.04), AGEN: 3.85 (unch), INO: 9.11 (-0.09), NBS: 3.27 (+0.02), OSIR: 14.87 (+0.13), TEVA: 57.09 (+0.33), ATHX: 1.30 (-0.03)
Stryker & Osiris Team Up to Market Viable Bone Matrix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:50PM CST
Under the partnership, Stryker Corporation (SYK) will attain exclusive, worldwide rights to Osiris' viable bone matrix under the name BIO4.
ANIP: 55.24 (+1.79), OSIR: 14.87 (+0.13), AFFX: 9.80 (+0.05), SYK: 96.00 (-0.61)
Osiris Announces a Strategic Partnership with Stryker for Marketing Osiris' Viable Bone Matrix
Business Wire - Mon Dec 22, 3:30PM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that it has entered into an exclusive, worldwide partnership with Stryker Corporation (NYSE:SYK) for the commercialization and development of Osiris' viable bone matrix tissue form. Stryker is a global leader in medical technology whose products and services are available in over 100 countries around the world. This partnership strategically aligns one of Osiris' leading regenerative medicine technologies with Stryker's innovative medical device portfolio; the resulting synergies will maximize the market potential.
OSIR: 14.87 (+0.13), SYK: 96.00 (-0.61)
Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.20 (unch), MDT: 74.08 (+0.31), PSTI: 2.46 (unch), OSIR: 14.87 (+0.13), OPXA: 0.80 (+0.01), FCSC: 2.38 (+0.04), BAX: 74.45 (-0.04), CYTX: 0.48 (-0.01)
Commit To Buy Osiris Therapeutics At $11, Earn 9.9% Annualized Using Options
at The Street - Mon Dec 15, 11:18AM CST
Investors considering a purchase of Osiris Therapeutics Inc shares, but cautious about paying the going market price of $12.83/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
OSIR: 14.87 (+0.13)
Is Osiris Therapeutics (OSIR) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 7:34AM CST
Osiris Therapeutics is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
OSIR: 14.87 (+0.13)
New medical chief at Osiris
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 8:13AM CST
OSIR: 14.87 (+0.13)
Osiris Therapeutics Announces Expansion of the Leadership Team
Business Wire - Wed Dec 03, 7:02AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, is pleased to announce the expansion of the management team with the appointment of Adrian Mollo as General Counsel and Dr. Jon Hopper as Chief Medical Officer, both reporting to Lode Debrabandere, Ph.D., President and Chief Executive Officer. Gregory Law also recently joined the Osiris management team as Vice President of Finance and Principal Accounting Officer, reporting to Philip Jacoby, Chief Financial Officer.
OSIR: 14.87 (+0.13)
Osiris Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Mon Dec 01, 7:01AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 3:00 p.m. ET in New York City.
OSIR: 14.87 (+0.13)
Osiris Therapeutics Earnings Hindsight: Down 2.8% in Last 17 Days (OSIR)
Comtex SmarTrend(R) - Mon Nov 24, 9:24AM CST
Two weeks ago on November 7th, 2014 Osiris Therapeutics (NASDAQ:OSIR) reported earnings and analysts, on average, expected a loss of $0.02 on sales of $14.8 million. Osiris Therapeutics actually reported earnings of $0.02 per share on sales of $17.2 million, beating EPS estimates by $0.04 and beating revenue estimates by $2.4 million. Since the company's report, shares of Osiris Therapeutics have fallen from $13.50 to $13.12, representing a loss of 2.8% in the past 17 days.
OSIR: 14.87 (+0.13)
Earnings Look Back: Osiris Therapeutics Is Down 3.3% Since Reporting Quarterly Results 1 Week Ago (OSIR)
Comtex SmarTrend(R) - Mon Nov 17, 3:25PM CST
When Osiris Therapeutics (NASDAQ:OSIR) reported earnings a week ago on November 7th, 2014, analysts, on average, expected the company to report a loss of $0.02 on sales of $14.8 million. Osiris Therapeutics actually reported earnings of $0.02 per share on sales of $17.2 million, beating EPS estimates by $0.04 and beating revenue estimates by $2.4 million. Shares of Osiris Therapeutics have slipped from $13.50 to $13.05, representing a loss of 3.3%, since the company reported earnings 10 days ago.
OSIR: 14.87 (+0.13)
Osiris Therapeutics to Present at the Canaccord Genuity Medical Technology and Diagnostics Forum
Business Wire - Mon Nov 17, 7:02AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the Canaccord Genuity Medical Technology and Diagnostics Forum on Thursday, November 20, 2014 at 9:00 a.m. ET in New York City.
OSIR: 14.87 (+0.13)
Osiris Therapeutics Beats on Q3 Earnings & Revenues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 11, 8:00AM CST
Osiris Therapeutics (OSIR) performed well above expectations with revenues increasing significantly.
CYTK: 5.87 (+0.35), BIIB: 340.89 (+5.13), OSIR: 14.87 (+0.13), AMAG: 43.02 (+0.90)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 4:35PM CST
AGTC: 20.96 (+0.22), BXE: 3.52 (-0.06), ROKA: 4.60 (-0.09), ALNY: 93.52 (+0.97), NCT: 4.68 (-0.02), SSRI: 4.66 (+0.26), ABCB: 25.94 (+0.23), OSIR: 14.87 (+0.13), XCO: 2.38 (-0.03), JDST: 19.26 (-2.21)
Osiris Therapeutics' (OSIR) CEO Lode Debrabandere on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 11:00AM CST
OSIR: 14.87 (+0.13)
Osiris ups revenues 149% in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:19AM CST
OSIR: 14.87 (+0.13)
Osiris Therapeutics (OSIR) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Fri Nov 07, 7:55AM CST
OSIR: 14.87 (+0.13)
Osiris Therapeutics beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:10AM CST
OSIR: 14.87 (+0.13)